Dermata Therapeutics, Inc. (DRMA) 股票分析

公司概述

Dermata Therapeutics, Inc. operates as a late-stage medical dermatology company dedicated to the identification, development, and commercialization of pharmaceutical product candidates designed for treating medical skin diseases and addressing aesthetic applications. The enterprise functions within the Healthcare sector, specifically the Biotechnology industry, positioning it as an entity focused on high-potential, early-to-mid-stage innovation rather than established consumer product sales. As of the latest data, the company maintains a market capitalization of $4.87M and employs a workforce of 9 individuals to execute its strategic roadmap. The combination of a sub-$5M market cap and negligible reported annual revenue indicates that Dermata Therapeutics is a micro-cap biotechnology firm currently in a capital-intensive development phase, where the primary value driver is the clinical progress of its lead product candidate, XYNGARI, which has advanced to Phase 3 clinical trials.

财务健康

The company reports a net income of $-7,558,557 over the trailing twelve months, while revenue and EBITDA figures are listed as N/A, a pattern typical for biotechnology firms pre-commercialization where research and development expenses significantly outweigh current sales. The substantial negative net income relative to the absence of reported revenue reveals a cost structure dominated by heavy investment in clinical trials and operational overhead necessary to advance XYNGARI through regulatory approval. Free cash flow stands at $-5,016,645, indicating that the company is burning cash to fund its operations and clinical development, which necessitates continuous access to external capital or internal reserves to maintain solvency. All three margin metrics—Gross Margin, Operating Margin, and Profit Margin—are recorded at 0.0%, reflecting the standard accounting treatment for pre-revenue entities that have not yet generated sales to cover their variable or fixed costs. The balance sheet holds $7.52M in cash against $0 in debt, creating a conservative financial posture that provides a significant runway to continue operations without immediate refinancing risk. The current ratio of 4.79 suggests robust short-term liquidity, as the company possesses current assets that are nearly five times its current liabilities, ensuring it can meet its immediate obligations comfortably. Return on Equity is -194.2% and Return on Assets is -85.3%, metrics that mathematically reflect the heavy investment required to generate future value rather than current profitability, signaling that management is prioritizing asset growth and clinical milestones over immediate shareholder returns.

估值评估

Trailing P/E and Forward P/E ratios are presented as N/A and -0.31 respectively, where the negative forward P/E is a mathematical artifact of negative earnings rather than a traditional valuation multiple, implying that the market is pricing the stock based on future potential rather than current profitability. The Price to Book ratio is 0.52, which indicates that the market values the company at roughly half of its net asset book value, suggesting a deep discount relative to tangible assets but also highlighting the intangible value locked in the clinical pipeline. Price to Sales and EV/EBITDA metrics are unavailable due to the lack of revenue and EBITDA data, meaning traditional sales-based or earnings-based valuation models cannot be applied to this pre-revenue biotechnology entity. The stock has traded between a 52-week high of $9.90 and a 52-week low of $1.10, illustrating significant volatility common in small-cap biotech stocks where price discovery is driven by clinical data releases. The current price sits within this wide range, reflecting the speculative nature of the investment where valuation is contingent on the successful outcome of Phase 3 trials rather than historical financial performance. The Beta of 0.50 indicates that the stock's price volatility is roughly half that of the broader market, suggesting it may be less sensitive to general market movements but subject to specific sector risks and binary clinical event impacts.

Growth & Income

Revenue growth and earnings growth rates are both listed as N/A, as the company has not yet achieved commercial revenue generation to establish a year-over-year growth trajectory for comparison. Since the company does not pay dividends, the dividend yield and payout ratio are both N/A and 0.0% respectively, indicating a strategy where earnings—though currently negative—are theoretically destined to be reinvested entirely into research, development, and clinical expansion rather than distributed to shareholders. The absence of a payout ratio confirms that the company is in an accumulation phase, leveraging its cash reserves to fuel the development of XYNGARI rather than providing income to investors. The overall growth and income profile is characterized by a high-risk, zero-dividend structure where the sole expectation for future value appreciation relies on the successful commercialization of its pharmaceutical product candidates after clearing regulatory hurdles.